EU shores up pandemic defences with 478m flu vaccine deal
According to data from the health analytics firm Airfinity, the EU now has signed agreements with seven manufacturers to reserve vaccines – including a new deal unveiled last week with CSL Seqirus for a further 27m doses.
Although governments including Canada and the UK have reserved more doses per person, the EU has the largest and most diverse supply chain for a possible influenza pandemic.
As reported in the Lancet last week, the recent emergence of highly pathogenic H5N1 avian influenza virus infections in dairy cows and humans in the US has 'raised alarms regarding the potential for a pandemic'.
'Over 995 dairy cow herds and at least 70 humans have been affected, including cases of severe disease and the first reported H5N1-related death in the U.S'.
This emerging threat has caused health authorities across the globe to quietly start planning for a possible spillover to humans, with a clear focus on vaccine supply.
The shots the EU now has on standby do not constitute a stockpile. Rather than amassing a store of ready-to-use vaccines which protect against known strains of bird flu, the bloc has bet big on reserving access to outbreak-specific shots.
These would be produced after a pandemic was declared and the exact strain of the virus was known – giving the best chance of the jabs being efficacious in humans.
Richard Bennett, lead analyst at Airfinity, said the EU was also hedging its bets by doing deals with seven different firms.
'This diversification reduces the risk of supply disruption if one manufacturer encounters production issues, and prevents monopolising capacity from any single supplier,' he said.
Other countries have also set about reserving access to as-yet-unmade vaccines. Germany has secured production capacity or 400 million doses, under a framework that would also distribute manufactured jabs to the wider European Union.
Vaccine resilience and flexibility
Meanwhile the UK and Canada have reserved 100m and 80m doses respectively. Although this equates to more shots per person than the EU has access to (1.5 per capita for Britain, two for Canada and one for the EU), the supply chains are less diverse. Canada is reliant on GSK, while the UK has a single deal with CSL Seqirus, according to Airfinity.
Unlike the other countries included in the analysis, the US does not have enough doses to cover its entire population. Mr Bennet said this is unsurprising, 'given previous [US] demand for pandemic vaccines'.
During the H1N1 'swine flu' outbreak in 2009, national vaccine coverage was just 27 per cent, though this jumped to 69.5 per cent during the coronavirus pandemic.
Still, the superpower has 250m doses of pandemic flu shots reserved with CSL Seqirus and Sanofi, plus a stockpile of 20m shots against known strains of bird flu already circulating.
'Most countries depend on a handful of manufacturers for pandemic flu vaccines. Seven companies produce over 85 per of global supply, leaving national stockpiles vulnerable to geopolitical tensions, production delays, or supply chain shocks,' the Airfinity analysis warned.
'The EU has reduced reliance on single suppliers by securing contracts with multiple manufacturers, creating a more resilient and flexible vaccine procurement strategy during emergencies.'
Production delays and vaccine nationalism
The coronavirus pandemic highlighted the threat of vaccine nationalism, production delays and export restrictions. India's export bans, for instance, stalled the rollout of shots from Covax, which sought to buy immunisations for developing countries.
The US also imposed limits on the export of vaccines and the critical equipment and materials needed to make them, while the EU threatened to block the export of AstraZeneca shots made for the UK government in the Netherlands.
Ray Longstaff, director for Pandemic and Outbreak Preparedness and Response at CSL Seqirus, said the company has designed its manufacturing network and contracts to ensure minimum disruption in the face of these sorts of threats.
'In our agreements, we have supplied safeguards and comprehensive information about how we will not only meet the timelines … but also the kind of preparedness measures that we put in place to protect supply chains,' he said. 'It's something that we take very seriously.'
CSL Seqirus Liverpool's refrigerated warehouse, where vaccines for flu – including H5N1 – are stored before shipment - Simon Townsley/The Telegraph
The company – which has manufacturing sites in the UK, US and Australia – is one of the world's largest producers of seasonal flu shots. It also has a bird flu vaccine programme, plus a separate initiative to create pandemic-specific vaccines. If the WHO declared a pandemic, all manufacturing would switch to solely respond to the given outbreak.
The pharmaceutical firm's latest deal reserves 27.5m pandemic flu doses for 17 participating EU member states, which would be manufactured at the CSL Seqirus site in Liverpool using an egg-based production method. The company now has deals to supply pandemic shots to more than 30 governments worldwide, including the UK.
Mr Longstaff said he could not discuss specifics of the contracts – which include reservation fees that are invested in 'maintaining readiness and preparedness' – and downplayed the ramifications of potential tensions between governments in a pandemic scenario.
He also stressed that the company would support lower income countries through the WHO's Pandemic Influenza Preparedness (PIP) framework. Agreed after the 2009 swine flu outbreak, this requires companies to donate 10 per cent of their pandemic influenza shots, in real time.
This principle has also been incorporated into the new WHO pandemic treaty, set to be approved at the World Health Assembly in Geneva later this month, in an attempt to ensure that wealthy countries are not the only ones who have access to medical countermeasures in the event of an outbreak.
Protect yourself and your family by learning more about Global Health Security
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Weedkiller ingredient widely used in US can damage organs and gut bacteria, research shows
The herbicide ingredient used to replace glyphosate in Roundup and other weedkiller products can kill gut bacteria and damage organs in multiple ways, new research shows. The ingredient, diquat, is widely employed in the US as a weedkiller in vineyards and orchards, and is increasingly sprayed elsewhere as the use of controversial herbicide substances such as glyphosate and paraquat drops in the US. But the new piece of data suggests diquat is more toxic than glyphosate, and the substance is banned over its risks in the UK, EU, China and many other countries. Still, the EPA has resisted calls for a ban, and Roundup formulas with the ingredient hit the shelves last year. Related: 'We thought we'd got the numbers wrong': how a pristine lake came to have the highest levels of 'forever chemicals' on record 'From a human health perspective, this stuff is quite a bit nastier than glyphosate so we're seeing a regrettable substitution, and the ineffective regulatory structure is allowing it,' said Nathan Donley, science director with the Center For Biological Diversity, which advocates for stricter pesticide regulations but was not involved in the new research. 'Regrettable substitution' is a scientific term used to describe the replacement of a toxic substance in a consumer product with an ingredient that is also toxic. Diquat is also thought to be a neurotoxin, carcinogen and linked to Parkinson's disease. An October analysis of EPA data by the Friends of the Earth non-profit found it is about 200 times more toxic than glyphosate in terms of chronic exposure. Bayer, which makes Roundup, faced nearly 175,000 lawsuits alleging that the product's users were harmed by the product. Bayer, which bought Monsanto in 2018, reformulated Roundup after the International Agency for Research on Cancer classified glyphosate as a possible carcinogen. The new review of scientific literature in part focuses on the multiple ways in which diquat damages organs and gut bacteria, including by reducing the level of proteins that are key pieces of the gut lining. The weakening can allow toxins and pathogens to move from the stomach into the bloodstream, and trigger inflammation in the intestines and throughout the body. Meanwhile, diquat can inhibit the production of beneficial bacteria that maintain the gut lining. Damage to the lining also inhibits the absorption of nutrients and energy metabolism, the authors said. The research further scrutinizes how the substance harms the kidneys, lungs and liver. Diquat 'causes irreversible structural and functional damage to the kidneys' because it can destroy kidney cells' membranes and interfere with cell signals. The effects on the liver are similar, and the ingredient causes the production of proteins that inflame the organ. Meanwhile, it seems to attack the lungs by triggering inflammation that damages the organ's tissue. More broadly, the inflammation caused by diquat may cause multiple organ dysfunction syndrome, a scenario in which organ systems begin to fail. The authors note that many of the studies are on rodents and more research on low, long-term exposure is needed. Bayer did not immediately respond to a request for comment. Despite the risks amid a rise in diquat's use, the EPA is not reviewing the chemical, and even non-profits that push for tighter pesticide regulations have largely focused their attention elsewhere. Donley said that was in part because US pesticide regulations are so weak that advocates are tied up with battles over ingredients like glyphosate, paraquat and chlorpyrifos – substances that are banned elsewhere but still widely used here. Diquat is 'overshadowed' by those ingredients. 'Other countries have banned diquat, but in the US we're still fighting the fights that Europe won 20 years ago,' Donley said. 'It hasn't gotten to the radar of most groups and that really says a lot about the sad and sorry state of pesticides in the US.' Some advocates have accused the EPA of being captured by industry, and Donley said US pesticide laws were so weak that it was difficult for the agency to ban ingredients, even if the will exists. For example, the agency banned chlorpyrifos in 2022, but a court overturned the decision after industry sued. Moreover, the EPA's pesticides office seems to have a philosophy that states that toxic pesticides are a 'necessary evil', Donley said. 'When you approach an issue from that lens there's only so much you will do,' he said.
Forbes
2 hours ago
- Forbes
European Auto Investors May Be Underestimating Trump Tariff Threat
Vector illustration. The mood music is calm as European auto investors await the deadline on talks between the U.S. and the European Union on tariffs. But before getting too complacent, they should remember President Donald Trump's goal is to end what he considers to be long-term European trade gerrymandering that might inhibit a deal on autos. President Trump paused his attempt to reform overall tariffs on U.S. trade for 90 days and that ends July 9. The U.S. imposed a 20% tariff on European goods but quickly suspended it ahead of the deadline. Last month President Trump threatened a 50% tariff because the talks were bogged down, but after speaking with European Commission President Ursula von der Leyen, he reverted to July 9. HSBC Global Research reflects general confidence that a disastrous tariff war can be averted, at least in the automotive business. 'Confidence appears to be growing around a deal with the U.S. that sees a degree of tariff walk-back. If this comes, it is likely that earnings, especially for the German (manufacturers) will get a boost, but we're not convinced it will reverse all the pain,' HSBC Global said in a report. As well as worrying about the possible damage a tariff war with the U.S. might do, European auto stocks have been rocked by a range of negatives. These include a slowdown in China, where Volkswagen , BMW and Mercedes have seen traditionally huge profits pared back, Chinese impact in Europe as their imports advance, while high local interest rates and a sluggish economy hurt consumer confidence. Tariff concerns ease Since April, investor concerns about the possible U.S. tariff burden have eased, investment bank UBS said. Bernstein Research, in a recent research note, looked at the impact on European manufacturers of moderate pressure from higher U.S. automotive tariffs. 'BMW and Mercedes are better positioned due to their substantial U.S. production footprints, and can increase U.S. output without incremental (capital spending). Ferrari's strong brand pricing power limits its EBIT (earnings before interest and tax) impact,' the report said. 'By contrast, VW and Porsche retain notable exposure, with EBIT impacts ranging from €500 million to €900 million ($590 million to $1.06 billion) depending on pass-through assumptions,' according to the report. Impossible to predict 2009 Mercedes Benz CLK Cabriolet. Artist Unknown. (Photo by National Motor Museum/Heritage ...) Professor Ferdinand Dudenhoeffer, director of Germany's Center for Automotive Research, said he finds it impossible to predict President Trump's actions, but hopes for a solution that would eliminate tariffs on both sides. 'My suggestion would be as follows: No tariffs on cars and car parts. And that includes semiconductors and software and IT for cars, carmakers and suppliers,' Dudenhoeffer said in an email exchange. 'So, if Mercedes builds the CLK (two-seater sports car) in Stuttgart, they need semiconductors from Nvidia and software from Google Maps. And it's not just Nvidia and Alphabet, but also Microsoft, Amazon, Oracle, Qualcomm, and others that "export" software, semiconductors, and cloud solutions from the U.S. to Europe. Very large budgets are at stake. Not just for the automakers, but also for the parts manufacturers and suppliers.' 'So it could be that simple: No tariffs on cars and car parts in either direction. The U.S. would gain more than with a 33% tariff on a few imports of large sedans or sports cars,' he said. Trump has said international competition, particularly from the E.U., has benefited from the U.S.'s traditional low tariffs, which hasn't been reciprocated. He insists his ultimate goal is free trade. Trump determined to fix long-term EU duplicity Earlier this year, former U.S. ambassador to the EU Gordon Sondland, said in a BBC interview Trump is determined to put right what he considers long-term unfairness by the EU through tariffs and non-tariff barriers. Ferrari California. Ferrari looks imune from even the harshest tariffs. Sondland said the EU imposes hidden barriers on American products. For cars, that can mean different safety standards. For food, there are also standards the EU doesn't like. Hormone-fed beef is one area of contention. 'If we sell you a vegetable or a car or a product if it's safe to use in the U.S. it should deemed to be safe to use in the EU,' Sondland said, adding that he didn't speak for the Trump administration. He was asked to sum up Trump's tariff plan for Europe and the world. 'The U.S. is tired of talking about impediments to its foreign trade and wants action now,' he said. Sondland was the ambassador to the EU during Trump's first term. America's big advantage in services Europeans point out that while its trade deficit with the U.S. is large, the American advantage in services like high-tech, media and software is even bigger. Before Trump initiated the tariff changes, the U.S. charged European automakers 2.5%, while Europe charged U.S. imports 10%. Automotive consultants JATO Dynamics pointed out the huge imbalance in U.S./EU auto trade, with 821,000 vehicles moving from east to west in 2024 and only 188,100 moving in the other direction. In a report, JATO said this was due in part to the lack of global appeal of U.S. made vehicles. This could spur a wave of U.S. protectionism. Computer generated 3D illustration with a monster truck isolated on white background 'A new wave of U.S. protectionism could dramatically reshape the global automotive industry, as the United States looks to redress a persistent imbalance with the European Union in the trade of vehicles.' JATO said in a report. The report said U.S. car buyers wanted much bigger vehicles than Europeans. Europe doesn't want big SUVs, pickup trucks? 'Pick-up trucks and large SUVs, in which American carmakers have largely specialized, have been a double-edged sword,' JATO global analyst Felipe Munoz commented. 'While they have been a major source of profitability for America's two largest automakers – General Motors and Ford – demand for these vehicles in other markets does not exist on the same scale as in the U.S.,' Munoz said. 'Without a concerted effort by U.S. manufacturers to develop truly global products that align with regulatory requirements and market-specific preferences, this imbalance is likely to persist,' Munoz said. President Trump might point out this was another example of hidden EU barriers to U.S. imports, because Europeans might well be eager to buy huge U.S. SUVs and pickup trucks, but were unable to afford to use them because of massive fuel taxes. It costs Europeans around 3 times as much to fill their SUVs and sedans as Americans because of massive taxes which would be unacceptable in the U.S.
New York Post
2 hours ago
- New York Post
Trump can't give up the fight against foreign meddling in US tech
President Donald Trump last month got Canada to kill a blatantly unfair tax on US-based companies, but the fight against foreign meddling in America's tech industry has a long way to go. Canada's Digital Services Tax was set to slap companies like Google, Meta, Amazon, Uber and Airbnb with a 3% levy on revenue from Canadian users — until Trump canceled trade talks over what he rightly slammed as an 'egregious' move. Prime Minister Mark Carney promptly nixed the fee hours before it would've kicked in. Good: The tax was a shameless cash grab at the expense of American companies — and it was retroactive, demanding US-based tech firms fork over a whopping $2 billion. Note that the Biden administration also opposed the tax, and even whined that it might violate the USMCA trade agreement — but did nothing to actually stop it. Making Carney back down is fresh proof that Trump's big-stick trade tactics can work — and work to protect cutting-edge knowledge-based industries, not just brick-and-mortar manufacturing. It also shows that, despite all the ink spilled over Elon Musk's tiff with Trump, the tech industry still has plenty of reason to stay friendly with the administration. Especially since, as the prez pointed out on TruthSocial, Canada was just seeking to copy the European Union, which shamelessly uses its Digital Markets and Digital Services Acts to fill its coffers and bend US tech to its will. Six of seven tech companies the European Commission has highlighted as 'gatekeepers' to be reined in are American: Google, Apple, Meta, Amazon, Microsoft and The EU has already hit Apple and Meta this year with massive fines for allegedly breaking the Digital Markets Act's antitrust rules. Keep up with today's most important news Stay up on the very latest with Evening Update. Thanks for signing up! Enter your email address Please provide a valid email address. By clicking above you agree to the Terms of Use and Privacy Policy. Never miss a story. Check out more newsletters Far worse: The Digital Services Act chills free expression by threatening steep financial repercussions against companies that allow speech that the EU considers 'disinformation,' 'hate speech' or threats to 'civil discourse' — concepts so nebulous that it's hard to see how companies can comply without stomping on the First Amendment. It's beyond unacceptable for Brussels to determine what Americans can say on American–owned sites. The EU's legal harassment of US-based tech firms is so egregious that Trump aide Peter Navarro slammed it as 'lawfare' in April. These 'fines' are basically tariffs by another name — milking successful American companies by creating strict regulations that target them especially. Canada clearly meant to get its own slice of that pie, only for Trump to slap down Ottowa's grasping hand. Making the Europeans back off should be high on the president's agenda as he starts his next tariff offensive. Don't let America's trade partners reap the benefits of our thriving, innovative tech industry while spitting on the free-speech and free-market ideals that make it possible.
